GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » Capex-to-Operating-Income

Actelion (XSWX:ATLNE) Capex-to-Operating-Income : 0.04 (As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Actelion's Capital Expenditure for the three months ended in Mar. 2017 was CHF-7.94 Mil. Its Operating Income for the three months ended in Mar. 2017 was CHF214.45 Mil.

Hence, Actelion's Capex-to-Operating-Income for the three months ended in Mar. 2017 was 0.04.


Actelion Capex-to-Operating-Income Historical Data

The historical data trend for Actelion's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Capex-to-Operating-Income Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.06 0.05 0.07 0.07

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.13 0.04 0.12 0.04

Competitive Comparison of Actelion's Capex-to-Operating-Income

For the Biotechnology subindustry, Actelion's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actelion's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Actelion's Capex-to-Operating-Income falls into.



Actelion Capex-to-Operating-Income Calculation

Actelion's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2016 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-57.442) / 788.712
=0.07

Actelion's Capex-to-Operating-Income for the quarter that ended in Mar. 2017 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-7.935) / 214.446
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion  (XSWX:ATLNE) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Actelion Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Actelion's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (XSWX:ATLNE) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines